Characteristics of Developmental and Healing Process of Docetaxel-Induced Lower Limb Edema in Patients with Stage IV Breast Cancer: A Case Series

被引:0
|
作者
Imakata, Yuko [1 ,2 ]
Sugama, Junko [3 ]
Ichihashi, Sayumi [4 ]
Oohashi, Fumiya [2 ]
Kobayashi, Masato [5 ]
Oe, Makoto [4 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, Ishikawa, Japan
[2] Ishikawa Prefectural Nursing Univ, Dept Adult Nursing, Ishikawa, Japan
[3] Fujita Hlth Univ, Res Ctr Implementat Nursing Sci Initiat, Aichi, Japan
[4] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Hlth Sci, Dept Clin Nursing, Ishikawa, Japan
[5] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Hlth Sci, Dept Radiol Technol, Ishikawa, Japan
来源
PALLIATIVE MEDICINE REPORTS | 2023年 / 4卷 / 01期
关键词
chemotherapy; compression therapy; docetaxel; initial finding; severe edema; ultrasonography; TAXANE-BASED CHEMOTHERAPY;
D O I
10.1089/pmr.2022.0059
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Management of docetaxel-induced edema is important as severe edema may lead to discontinuation of chemotherapy. Patients with stage IV breast cancer (BC) treated with docetaxel have shown lower limb edema; however, details of its developmental and healing processes are unknown, and thus management strategies have not been established. The aim of this study was to investigate the characteristics of the development and healing process of docetaxel-induced lower limb edema in stage IV BC patients.Methods: This prospective observational study was conducted on patients with BC who were administered docetaxel between September 2020 and September 2021 at a National Hospital in Japan. Skin changes such as pitting test, circumference, along with ultrasound images and subjective symptom changes were evaluated. The progression of these changes was compared between patients with stage IV and non-stage IV disease.Results: Five patients were enrolled in the study, of which two and one patients with stage IV and non-stage IV disease, respectively, developed lower limb edema. Early signs of lower limb edema were observed in ultrasound images, 15 cm below the peroneal head, before edema was confirmed by the pitting test and subjective symptoms. In patients with stage IV disease, edema worsened to Grade 3, and reduced four months after the end of drug administration.Conclusion: For patients with stage IV disease, care should be initiated from the time the early signs are observed using ultrasound and continued for up to four months after the end of docetaxel administration.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [41] A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer
    Bates, M
    Lieu, D
    Zagari, M
    Spiers, A
    Williamson, T
    CLINICAL THERAPEUTICS, 1997, 19 (01) : 167 - 184
  • [42] Case series: Paclitaxel (P) and pegfigrastim (PF)-induced hypersensitivity pneumonitis (HSP) in breast cancer patients (pts)
    Cream, L.
    Barochia, A. C.
    Sivik, J.
    Kass, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] CD34+ cell yields are different following simultaneous or sequential doxorubicin/docetaxel induction chemotherapy in patients with previously untreated stage IV breast cancer.
    Schwartzberg, L
    Wilson-Relyea, B
    Birch, R
    Sysel, I
    Hazelton, B
    West, W
    BLOOD, 1999, 94 (10) : 342B - 342B
  • [44] Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients
    Xu Liang
    Jie Zhang
    Yulin Zhu
    Yuanli Lu
    Xinna Zhou
    Zheng Wang
    Jing Yu
    Ying Yan
    Lijun Di
    Li Che
    Hanfang Jiang
    Bin Shao
    Xiaoli Wang
    Huabing Yang
    Herbert Kim Lyerly
    Jun Ren
    Clinical and Translational Oncology, 2013, 15 : 331 - 334
  • [45] Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients
    Liang, Xu
    Zhang, Jie
    Zhu, Yulin
    Lu, Yuanli
    Zhou, Xinna
    Wang, Zheng
    Yu, Jing
    Yan, Ying
    Di, Lijun
    Che, Li
    Jiang, Hanfang
    Shao, Bin
    Wang, Xiaoli
    Yang, Huabing
    Lyerly, Herbert Kim
    Ren, Jun
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (04): : 331 - 334
  • [46] Effect of the Botanical Compound LCS101 on Chemotherapy-Induced Symptoms in Patients with Breast Cancer: A Case Series Report
    Samuels, Noah
    Maimon, Yair
    Zisk-Rony, Rachel Y.
    INTEGRATIVE MEDICINE INSIGHTS, 2013, 8
  • [47] Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
    Akpo, Esse I. H.
    Jansen, Irshaad R.
    Maes, Edith
    Simoens, Steven
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [48] Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature
    Montero, Alberto J.
    Talebi, Tony N.
    Zhu, Ying
    Branch, Kevin D.
    Goldsberry, Grant T.
    Baker, Megan K.
    Gluck, Stefan
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (01) : E12 - E18
  • [49] A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus
    Bang, Sun-Hwi
    Yoon, Jeung-Won
    Cho, Chong-Kwan
    Shin, Ji-Eun
    Lee, Yeon-Weol
    Yoo, Hwa-Seung
    JOURNAL OF PHARMACOPUNCTURE, 2012, 15 (02) : 31 - 35
  • [50] The impact of combined Gua Sha and myofascial release techniques on upper limb dysfunction in patients with breast cancer and axillary web syndrome: a prospective case series study
    Sun, Ruping
    Liao, Yanyan
    SUPPORTIVE CARE IN CANCER, 2025, 33 (04)